
Accuray (NSDQ:ARAY) won 510(k) clearance from the FDA for the latest iteration of its CyberKnife radiosurgery device.
Chief commercial officer Kelly Londy told MassDevice.com that the Sunnyvale, Calif.-based medical device company is launching the product immediately.
Unlike other radiosurgery devices, which deliver a targeted beam of radiation to destroy cancerous tumor cells, the CyberKnife M6 tracks and adjusts for any physical movement of the tumor.
Sign up to get our free newsletters delivered right to your inbox
"We’re really confident in CyberKnife being the only system on the market to track and correct automatically through the treatment plan," Londy told us. "It actually tracks the tumor as it moves. The robot can move in any direction, so it tracks and adjusts as the organ is shifting."
The device is also designed to allow for stereotactic radiosurgery and stereotactic body radiation therapy, expanding the number of patients eligible for treatment with the device.
Londy said the 510(k) clearance covers a full-body indication, meaning the CyberKnife M6 can be used to treat a variety of cancers.
Here’s a video of the CyberKnife M6 in action: